Radiolabeled peptides for tumor imaging with PET that can be produced with kits are currently in the spotlight of radiopharmacy and nuclear medicine. The diagnosis of neuroendocrine tumors in particular has been a prime example for the usefulness of peptides labeled with a variety of different radionuclides. Among those, 68 Ga and 18 F stand out because of the ease of radionuclide introduction (e.g., 68 Ga isotope) or optimal nuclide properties for PET imaging (slightly favoring the 18 F isotope). The in vivo properties of good manufacturing practice-compliant, newly developed kitlike-producible 18 F-SiFA-and 18 F-SiFAlin-(SiFA 5 silicon-fluoride acceptor) modified TATE derivatives were compared with the current clinical gold standard 68 Ga-DOTATATE for high-quality imaging of somatostatin receptor-bearing tumors. Methods: SiFA-and SiFAlin-derivatized somatostatin analogs were synthesized and radiolabeled using cartridge-based dried 18 F and purified via a C18 cartridge (radiochemical yield 49.8% ± 5.9% within 20-25 min) without high-performance liquid chromatography purification. Tracer lipophilicity and stability in human serum were tested in vitro. Competitive receptor binding affinity studies were performed using AR42J cells. The most promising tracers were evaluated in vivo in an AR42J xenograft mouse model by ex vivo biodistribution and in vivo PET/CT imaging studies for evaluation of their pharmacokinetic profiles, and the results were compared with those of the current clinical gold standard 68 Ga-DOTATATE. Results: Synthetically easily accessible 18 F-labeled silicon-fluoride acceptor-modified somatostatin analogs were developed. They exhibited high binding affinities to somatostatin receptor-positive tumor cells (1.88-14.82 nM). The most potent compound demonstrated comparable pharmacokinetics and an even slightly higher absolute tumor accumulation level in ex vivo biodistribution studies as well as higher tumor standardized uptake values in PET/CT imaging than 68 Ga-DOTATATE in vivo. The radioactivity uptake in nontumor tissue was higher than for 68 Ga-DOTATATE. Conclusion: The introduction of the novel SiFA building block SiFAlin and of hydrophilic auxiliaries enables a favorable in vivo biodistribution profile of the modified TATE peptides, resulting in high tumorto-background ratios although lower than those observed with 68 Ga-DOTATATE. As further advantage, the SiFA methodology enables a kitlike labeling procedure for 18 F-labeled peptides advantageous for routine clinical application.
Radiolabeled peptides for tumor imaging with PET that can be produced with kits are currently in the spotlight of radiopharmacy and nuclear medicine. The diagnosis of neuroendocrine tumors in particular has been a prime example for the usefulness of peptides labeled with a variety of different radionuclides. Among those, 68 Ga and 18 F stand out because of the ease of radionuclide introduction (e.g., 68 Ga isotope) or optimal nuclide properties for PET imaging (slightly favoring the 18 F isotope). The in vivo properties of good manufacturing practice-compliant, newly developed kitlike-producible 18 F-SiFA-and 18 F-SiFAlin-(SiFA 5 silicon-fluoride acceptor) modified TATE derivatives were compared with the current clinical gold standard 68 Ga-DOTATATE for high-quality imaging of somatostatin receptor-bearing tumors. Methods: SiFA-and SiFAlin-derivatized somatostatin analogs were synthesized and radiolabeled using cartridge-based dried 18 F and purified via a C18 cartridge (radiochemical yield 49.8% ± 5.9% within 20-25 min) without high-performance liquid chromatography purification. Tracer lipophilicity and stability in human serum were tested in vitro. Competitive receptor binding affinity studies were performed using AR42J cells. The most promising tracers were evaluated in vivo in an AR42J xenograft mouse model by ex vivo biodistribution and in vivo PET/CT imaging studies for evaluation of their pharmacokinetic profiles, and the results were compared with those of the current clinical gold standard 68 Ga-DOTATATE. Results: Synthetically easily accessible 18 F-labeled silicon-fluoride acceptor-modified somatostatin analogs were developed. They exhibited high binding affinities to somatostatin receptor-positive tumor cells (1.88-14.82 nM). The most potent compound demonstrated comparable pharmacokinetics and an even slightly higher absolute tumor accumulation level in ex vivo biodistribution studies as well as higher tumor standardized uptake values in PET/CT imaging than 68 Ga-DOTATATE in vivo. The radioactivity uptake in nontumor tissue was higher than for 68 Ga-DOTATATE.
Conclusion:
The introduction of the novel SiFA building block SiFAlin and of hydrophilic auxiliaries enables a favorable in vivo biodistribution profile of the modified TATE peptides, resulting in high tumorto-background ratios although lower than those observed with 68 Ga-DOTATATE. As further advantage, the SiFA methodology enables a kitlike labeling procedure for 18 F-labeled peptides advantageous for routine clinical application. Radi olabeled peptides have emerged as valuable imaging tools for PET, although their clinical availability is still limited (1). These peptides are mostly labeled with radiometals such as 68 Ga and 64 Cu but also with 18 F (2-6). Although 68 Ga-labeled peptides exhibit favorable properties in clinical routine imaging, the resolution of the obtained PET images and thus sensitivity could be further improved using 18 F (7). Even more importantly, the widespread availability of 18 F would make such tracers more accessible. Furthermore, the availability and clinical use of 68 Ga-based tracers have been less than optimal because of the limited availability of the generators and their uncertain regulatory status. As there is an urgent demand in clinical diagnostic oncology for tumor-specific radiolabeled compounds depicting even very small tumors and metastases to compensate for the shortcomings of 18 F-FDG (8, 9) , the development of 18 F-labeled peptides is worth exploring. 18 F represents one of the most attractive radionuclides because of its accessibility and low positron energy allowing for high-resolution in vivo images. However, only a few clinical PET imaging sites routinely offer 18 F-radiolabeled peptides as a result of the typically difficult radiochemistry involved in peptide labeling with 18 F (10,11) . Therefore, new labeling approaches have been developed, especially over the last decade (12) (13) (14) (15) (16) . One of these approaches takes advantage of the thermodynamically favored formation of silicon-18 F bonds (silicon-fluoride acceptor [SiFA] chemistry, Fig. 1 ) (17) (18) (19) (20) (21) (22) (23) . However, in vitro and in vivo studies revealed inherent difficulties for its in vivo applicability: the unalterably high lipophilicity of the silicon-containing building block necessary for the in vivo stability of the Si- 18 F bond leads to changes in the pharmacokinetic properties of the accordingly derivatized peptides (19, 24) . Nevertheless, the radiolabeling of SiFA is exceptionally mild, proceeds without forming side products, and can be performed by even untrained personnel (17) , rendering this technique ideally suited for a kit-labeling approach similar to 99m Tc radiochemistry for SPECT imaging.
To reduce the lipophilicity of SiFA-modified peptides, hydrophilic linkers and amino acids such as aspartic acid were introduced into the peptide sequence in this study together with a SiFA building block containing a permanent positive charge: SiFAlin (Figs. 1 and 2) (25, 26) . Most recently, Perrin's group introduced 18 F-AMBF 3 -TATE for somatostatin receptor (SSTR) imaging, proving that a supposedly noncanonical labeling methodology based on isotopic exchange on trifluoroborates delivers an imaging agent of high specific activity and promising in vivo characteristics ( Fig. 2) (27) .
The main goal of our study was to prove the applicability of the SiFA approach for the labeling of clinically relevant peptides by developing a SiFAlin-derivatized Tyr 3 -octreotate (TATE) that matches or surpasses the targeting ability of the current gold standard 68 Ga-DOTATATE (Fig. 2) for SSTR in vivo imaging with PET, thus overcoming 68 Ga limitations in terms of availability and image resolution.
MATERIALS AND METHODS

Chemistry
Synthesis of Peptides by Solid-Phase Peptide Synthesis. SiFA-and SiFAlin-derivatized somatostatin analogs were synthesized as described earlier (17, 28) . Details can be found in the supplemental information (supplemental materials are available at http://jnm.snmjournals.org).
18 F-Fluoride Radiolabeling and Quality Control of Peptides. The radiolabeling procedure was performed as previously described (17) . In brief, aqueous 18 F-F 2 was trapped on a cartridge (Sep-Pak Accell Plus QMA Carbonate light, 46 mg; Waters) and dried with 20 mL of air and then rinsed with dry acetonitrile. Subsequently, a lyophilized mixture containing 110 mmol Kryptofix 2.2.2 (Merck) and 100 mmol KOH was dissolved in dry acetonitrile (500 mL). This freshly prepared solution was then used to elute the dried 18 F-F 2 from the cartridge (17, 29) . To the 18 F solution, 25 mL of a 1 M solution of oxalic acid in dry acetonitrile and a solution of 25 nmol of the precursor peptide were added. The isotopic exchange radiolabeling reaction proceeded within 5 min at ambient temperature with 70%-90% 18 F-fluoride incorporation. The reaction was quenched by the addition of 9 mL of 0.1 M HEPES (N-[2-hydroxyethyl]piperazine-N9-[2-ethanesulfonic acid]) buffer (pH 2) to receive the product in an aqueous acidic solution of approximately pH 5, which was subsequently purified with a SepPak C18 cartridge. After the product was trapped, reactants and solvent were removed by washing the cartridge with water for injection. After elution of the purified product peptide with 200-500 mL of ethanol, the solution was diluted with isotonic saline to a final ethanol concentration of 10% or less and sterile-filtered. Analytic radio-high-performance liquid chromatography showed a radiochemical purity of 98% or greater.
In Vitro Characterization of Radiotracers
Determination of Lipophilicities. Two microliters of the product solution were added to 800 mL n-octanol and 800 mL of phosphate buffer (0.05 M, pH 7.4). After vigorous shaking for 5 min, the phases were separated by centrifugation at 14,000g for 2 min. Three aliquots of 100 mL of each phase were measured in a g counter (27) .
Determination of Serum Stabilities. Two hundred microliters of the injectable peptide solution were mixed with 500 mL of human serum and incubated over a period of 120 min at 37°C. After 10, 30, 60, and 120 min, aliquots of 5 mL were withdrawn and analyzed by analytic radio-high-performance liquid chromatography. The analyses indicated an unaltered radiochemical purity of all tracers of 98% or greater after 120 min in human serum.
Competitive Receptor Binding Affinity Studies. A competitive receptor binding assay using viable AR42J cells (10 5 cells per well, cell culture is described in the supplemental information) was performed. The cells were incubated with 0.5 nM 177 Lu-DOTATATE (preparation protocol is available in the supplemental information) in the presence of different concentrations of each SiFA-derivatized peptide (0-250 nM) dissolved in binding buffer (containing 10 mM MgCl 2 , 1 mM CaCl 2 , 25 mM HEPES, 0.5% bovine serum albumin, pH 7.4) for 60 min at ambient temperature with gentle agitation. The removal of binding buffer and washing steps (2 · 100 mL and 1 · 200 mL ice-cold phosphate-buffered saline) were performed using a multiscreen vacuum manifold (Millipore). Subsequently, the cell-bound and internalized radioactivity was measured using a g counter (Cobra Quantum; Packard Canberra), and the inhibitory concentrations (IC 50 values) were calculated using a nonlinear regression algorithm (GraphPad Prism; GraphPad Software). The experiments were each performed in triplicate.
In Vivo Characterization of Radiotracers
All animal experiments respected German animal protection laws and protocols of the local committee.
Biodistribution Experiments. Injectable solutions (50 mL) containing 1.1-5.3 MBq of the respective radiolabeled peptide were injected intravenously. Animals (4-10/group) bearing AR42J tumors (details can be found in the supplemental information) were sacrificed after 60 or 90 min, and the organs were dissected. After determination of organ weight, the activity of the tissues was measured using a g counter (Wizard 2 2480; PerkinElmer) along with standards taken from the injected solution to determine the total injected activity. In blocking experiments, 200 mg of DOTATATE were coadministered together with the radiotracer.
Animal PET Imaging Studies. Nine tumor-bearing mice were injected with 4-8 MBq of the respective radiolabeled peptide ( 18 F-9, n 5 5, and 68 Ga-DOTATATE, n 5 4). A dynamic scan over 90 min and a subsequent CT image were acquired using a triple-modality Bruker Albira small-animal PET/SPECT/CT scanner.
RESULTS
SiFA Labeling Chemistry
Former studies introducing the SiFA labeling chemistry (first-generation SiFA-TATE (19) 18 F-fluoride incorporation within 5-10 min at ambient temperature. In in vivo scans, however, a pronounced liver uptake of 18 F-1 and hardly any radioactivity accumulation in tumor tissue was observed (Fig. 3A) because of the highly lipophilic character of the SiFA synthon. The introduction of a carbohydrate moiety (30) (Fig. 3B) .
To obtain more hydrophilic SiFA-bearing TATE derivatives better suitable for in vivo imaging of somatostatin-positive tumors due to more favorable pharmacokinetic properties, we introduced different hydrophilic auxiliaries into the peptide sequence and studied their influence on the tracer pharmacokinetics in vivo (26) .
Chemical and Radiosyntheses
The synthesis of the TATE derivatives was performed using standard Fmoc solid-phase peptide synthesis protocols (31) (the supplemental information provides details). Besides a carbohydrate moiety, we introduced additional hydrophilic auxiliaries such as PEGs (polyethylene glycols) of different lengths, 1 or 2 aspartic acids, and a permanently positively charged SiFAlin synthon based on a previously described charged SiFA building block ( Fig. 1) (25) .
The purification of the labeled peptides proved to be simple with a C18 cartridge purification. The 18 F-labeled peptides were obtained in high radiochemical yields of 49.8% 6 5.9% (n 5 20) and chemical as well as radiochemical purities of 98% or greater in only 20-25 min total synthesis time. This convenient 1-step 18 F-fluoride labeling strategy for peptides, proceeding with high efficiency and reliability, yields the 18 F-radiolabeled peptides with excellent specific activities of 44-63 GBq/mmol using starting activities of 3.3-6.7 GBq.
In Vivo Stability and Lipophilicity Determination
In accordance with previous studies, we found comparable results regarding the high stability of 18 F-labeled SiFA-and SiFAlin-TATE derivatives in human serum at 37°C over 120 min, showing no degradation of the radiolabeled peptides. The log D values (log D : n-octanol to water distribution coefficient determined in n-octanol/phosphate buffer, pH 7.4) of the 18 F-labeled peptides were determined to gauge the influence of the hydrophilic auxiliaries. A significantly reduced overall lipophilicity was found for all newly developed SiFA-and SiFAlin-derivatized somatostatin analogs, compared with first-and second-generation SiFA-TATE derivatives 1 and 3 (Supplemental Fig. 2) . Interestingly, the aspartic acids play the pivotal role in decreasing the lipophilicity because neither the different PEG spacers and SiFAlin (blue, PEG 1 : 9 and PEG 5 : 12) derivatives compared with second-generation (magenta, 3) were determined by competitive receptor binding affinity studies using AR42J cells and 177 Lu-DOTATATE as competitor. After incubation for 60 min in buffer at ambient temperature and successive washing steps, both cell-bound and internalized activity were measured using a γ counter. All experiments were performed in triplicate (error bars, mean ± SD).
nor the permanently positive charge at the SiFA moiety decreased the overall lipophilicity significantly.
In Vitro Receptor Affinity Studies
Although former studies displayed no loss of SSTR affinity (28) on chemical modification at the nonpharmacophoric N-terminus of the somatostatin analog TATE, a competitive cell-based affinity study was performed on viable rat pancreas carcinoma AR42J cells, known to overexpress SSTRs (32) . The binding assay demonstrated excellent IC 50 values in the low nanomolar range for the newly developed SiFA-TATE derivatives and thus a preserved binding affinity to SSTRs (Fig. 4; Supplemental Fig. 3 ).
Biodistribution Experiments of 18 F-SiFA-TATE Derivatives
To investigate the pharmacokinetic characteristics of the most promising 18 F-labeled candidates for in vivo tumor imaging, derivatives with 2 different PEG lengths (PEG 1 and PEG 5 ) and both SiFA-synthons (4 and 7 bearing SiFA, 9 and 12 bearing SiFAlin) were chosen for a comparative biodistribution study in AR42J tumor-bearing xenograft mice. The obtained results were compared with the current clinical gold standard 68 Ga-DOTATATE.
Once tumor sizes reached 0.2-0.8 cm 3 , solutions of the radiolabeled peptides 18 F-4, 18 F-7, 18 F-9, 18 F-12 and 68 Ga-DOTATATE were injected intravenously.
For biodistribution studies, the mice were sacrificed at 60 and 90 min after injection, and radioactivity measurements of necropsy tissue samples were performed (results of 60 min after injection are provided in Supplemental Fig. 4) . The results showed significantly higher tumor-to-organ ratios for the positively charged SiFAlin derivatives 18 F-9 and 18 F-12 than for their SiFA counterparts 18 F-4 and 18 F-7 ( Supplemental Fig. 6 ). The same was found at 90 min after injection: despite slightly lower absolute tumor accumulations than 18 F-4 and 18 F-7, the SiFAlin derivatives 18 F-9 and 18 F-12 showed significantly higher tumor-to-background ratios (Table 1) , thus rendering them better-suited for tumor visualization in vivo. Interestingly, the tracers containing a PEG 5 linker demonstrated an almost 2-foldhigher uptake in physiologically SSTR-positive tissues although the tumor uptake of PEG 1 -and PEG 5 -comprising peptide derivatives were comparable, thus making 18 F-SiFAlin-Glc-Asp 2 -PEG 1 -TATE ( 18 F-9) the most promising of the newly developed radiotracers.
When 18 F-9 was compared with the clinically established gold standard 68 Ga-DOTATATE, evaluated under identical experimental conditions, 18 F-9 demonstrated comparable pharmacokinetic properties (Fig. 5) , displaying a high and specific tumor uptake and low nontarget organ accumulations. Those results demonstrate that 18 F-9 is an interesting 18 F-labeled alternative to 68 Ga-DOTATATE, being as easily synthetically accessible as the latter, exhibiting more favorable physical decay characteristics such as a longer half-life and a significantly shorter maximum range of positrons.
To evaluate the potential of peptide 18 F-9 for in vivo tumor imaging, an additional animal PET study was performed. The outcomes of this study are shown in Figure 3C , illustrating the evolution of SiFA-modified 18 F-labeled TATE derivatives with regard to their in vivo pharmacokinetics.
Furthermore, to directly compare the image qualities achievable using the clinical gold standard 68 Ga-DOTATATE and 18 F-9, a comparative small-animal PET/CT study in SSTR-positive tumor-bearing animals was performed and the results are shown in Figure 6 .
These results demonstrate the high potential of newly developed compound 18 F-9 for clinical in vivo imaging of neuroendocrine tumors with PET.
DISCUSSION
18 F-SiFAlin-Glc-Asp 2 -PEG 1 -TATE ( 18 F-9) was identified from among a variety of new synthetically easily accessible SiFA-modified TATE derivatives being evaluated for 18 F-labeled peptide-based SSTR imaging (Supplemental Fig. 1) . 18 F-9 demonstrated-as compared with the current clinical gold standard 68 Ga-DOTATATEfavorable in vivo pharmacokinetic properties with higher absolute tumor uptake, very good tumor-to-normal-tissue ratios, and excellent spatial resolution of the images. Nevertheless, higher binding by most normal tissue will likely decrease contrast with 18 F-9 in direct comparison to 68 Ga-DOTATATE.
Importantly, the radiosynthesis of 18 F-9 was achieved within 20-25 min in a kitlike manner devoid of any special equipment or intricate purification procedures. The radiotracer was synthesized in radiochemical yields of 52.5% 6 4.9%, with specific activities of 44-63 GBq/mmol (1,200-1,700 Ci/mmol).
Similar to Perrin's synthesis of 18 F-AMBF 3 -TATE, the SiFAlinlabeling approach maintained all the benefits of the trifluoroborate chemistry, again highlighting the advantages of 18 F-labeling methods based on isotopic exchange (27) . The introduction of aspartic acids into the TATE derivatives was the key to sufficiently reduce the overall lipophilicity of 18 F-9 to a log D of 21.21 6 0.02. In addition, binding affinities of all SiFAlin-and auxiliarymodified peptides were in the nanomolar range, thus allowing for a strong interaction with the target receptors. The introduction of the novel SiFA building block SiFAlin (Fig. 1) , characterized by a permanent positive charge, resulted in improved tumor-tonontumor tissue ratios. These measures ultimately enabled a tumorspecific accumulation and renal clearance, which is mandatory for the overall quality of the resulting PET images. For 18 F-9, only renal excretion was observed in the AR42J tumor-bearing xenograft mouse model (Figs. 3C and 6B), with a maximum radioactivity accumulation in the tumor of 18.51 6 4.89 percentage injected dose per gram (%ID/g) at 60 min after injection compared with 14.10 6 4.84 %ID/g found for 68 Ga-DOTATATE under the same conditions as determined by ex vivo biodistribution experiments (Fig. 5) . A higher accumulation of radioactivity in normal tissue might, however, be detrimental to the overall image quality. The in vivo resistance of 18 F-9 to 18 F-hydrolysis is very high, as can be deduced from the low observed bone uptake of only 1.31 6 0.31 %ID/g at 90 min after injection (Fig. 5) . Moreover, the SiFAlin structure seems to have a pronounced positive influence on the tumor-to-organ ratios as well as on the pathway of excretion. In the used xenograft tumor model, 18 F-9 showed a promising biodistribution approaching the quality of 68 Ga-DOTATATE, which is a prerequisite for human application. In addition, the radioisotope 18 F has noteworthy physical advantages over other common radioisotopes used in SSTR imaging, yielding PET images of high resolution and quality, enabling a highly sensitive and efficient detection of neuroendocrine tumors. In studies in which quantification of uptake might be required, this approach is likely superior to that using 68 Ga-labeled peptides because of the significantly higher maximum energy of 68 Ga positrons as compared with those from 18 F (1,899 keV and 644 keV, respectively) (33) . The longer half-life of 18 F is also a major advantage, as it will allow for distribution of the tracer over longer distances in the same manner as 18 F-FDG, to reach PET centers not equipped with a 68 Ge/ 68 Ga generator or able to locally perform 18 F-labeling.
The direct comparison of both tracers, 68 Ga-DOTATATE and 18 F-9, with PET/CT imaging of tumor-bearing animals (Fig. 6) shows the excellent image quality that can be obtained using the 18 F-labeled compound 18 F-9, in terms of not only image resolution but also absolute tumor uptake. However, if transferred to a human imaging situation in which the tumor is likely localized abdominally and not peripherally, as in the animal tumor model, the background activity will indeed be a potential liability for accurate tumor visualization.
The fact that the synthesis of the radiolabeled compounds takes place at room temperature within 5 min; is devoid of any HPLC purification; can be made fully compliant with good manufacturing practice protocols; and proceeds in a kitlike manner, yielding the final 18 F-labeled peptide in high radiochemical yields within 20-25 min only renders this new radiotracer highly attractive toward a clinical application. The final success of the atypical SiFA-labeling methodology using the optimized SiFAlin in a preclinical setting opens up new avenues for nuclear medicine diagnostic imaging based on 18 F-labeled peptide imaging agents.
For a new radiotracer to become a routine clinical tool, requirements include not only good science and clinical scale up, but also carefully conducted multicenter clinical trials, ubiquitous availability, regulatory approval, and clinical acceptance funding by insurers and providers. These goals are likely easier to achieve with an 18 Flabeled radiopharmaceutical with access to an extensive central radiopharmacy network than with a significantly-shorter-half-life generator-produced tracer, which cannot be delivered over longer distances. Our belief is that the 18 F-9 tracer described in this article is an important step to achieving the goals identified herein. The kitlike formulation has the potential to make regulatory approval easier and ease acceptance by radiopharmacies. We propose to validate the safety and clinical efficacy of 18 F-9 in future phase I and II clinical trials.
CONCLUSION
We presented the synthesis and in vitro and in vivo evaluation of an auxiliary-derivatized 18 F-SiFAlin-TATE for SSTR imaging in a preclinical AR42J mouse xenograft model. The synthesis was developed as a kitlike procedure yielding multiple doses of the tracer with high specific activity. In vitro binding assays confirmed the high binding affinity of the tracers toward SSTRs. The direct comparison of tracer 18 F-9 with 68 Ga-DOTATATE in PET/CT imaging of tumor-bearing animals (Fig. 6) shows the excellent image quality, which can be obtained using the 18 F-labeled compound 18 F-9 in terms of image resolution and absolute tumor uptake.
Ex vivo and in vivo biodistribution data obtained with smallanimal PET/CT demonstrated the favorable pharmacokinetics and excellent tumor-to-nontarget tissue ratios in the preclinical mouse model, which warrant translation into human clinical trials. 
